Eupraxia Pharmaceuticals (EPRX) Other Operating Expenses (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Other Operating Expenses data on file, last reported at -$1.9 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 180533.49% year-over-year to -$1.9 million in Q1 2026; TTM through Mar 2026 was -$1.9 million, a 306.79% decrease from a year earlier, with the FY2024 full-year figure at $18611.0, up 484.05% from the prior year.
• Other Operating Expenses for Q1 2026 stood at -$1.9 million, down from -$1075.0 in the prior quarter.
• Over the last five years, Other Operating Expenses for EPRX reached as high as $2.1 million in Q4 2023 and fell as low as -$3.7 million in Q2 2023.
• Historically, Other Operating Expenses has averaged -$123759.8 across 4 years, with a median of $1075.0 in 2025.
• Across the five-year window, Other Operating Expenses jumped 345.17% in 2024 and tumbled 180533.49% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at $2.1 million in 2023, then slumped by 156.75% to -$1.2 million in 2024, then jumped by 99.91% to -$1075.0 in 2025, then plunged by 180333.49% to -$1.9 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were -$1.9 million in Q1 2026, -$1075.0 in Q4 2025, and $513119.0 in Q3 2025.